ArtiSential® for Rectal Cancer Surgery
- Conditions
- Rectal Cancer
- Interventions
- Device: ArtiSential®
- Registration Number
- NCT06236282
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a single surgeon in 2012-2022. Patients were divided into groups, use group vs. non-use group, based on the use or non-use of the ArtiSential®. The total mesorectal excision quality and resection margin status did not differ between the groups. ArtiSential® reduced operative time without impairing surgical quality or oncologic outcomes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 93
- mid-to-low rectal caner (witing 10cm of the anal verge)
- laparoscopic surgery
- combined surgery
- recurrent rectal cancer surgery
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description ArtiSential® Use ArtiSential® Laparoscopic low anterior resection, with use of both straight devices and articulated devices
- Primary Outcome Measures
Name Time Method Operation time 0 week To determine whether the use of articulated device can shorten total operative time
- Secondary Outcome Measures
Name Time Method TME quality (Operative outcome) 0 weeks Quality of total mesorectal excision to compare quality of surgery
Long-term Survival 2 year 2 year recurrence free survival and 2 year overall survival
Anastomotic leakage (postop outcome) 4 weeks anastomotic leakage within one month
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of